Developing theranostic approaches that capitalize on DKK1 and RSPO1 as therapeutic targets may pave the way for personalized treatment strategies tailored to the unique molecular profiles of ovarian cancer patients (Wang and Zhang, 2011; Klotz et al., 2022). The gene discussed is DKK1; the disease is ovarian cancer.